vimarsana.com

Page 2 - புதுப்பிக்கப்பட்டது ஜனவரி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ARPS Assessment Days

Your web browser is out of date. Update your browser for more security, speed and the best experience on this site. Find out more We use cookies and similar technologies to optimise your experience when using this site, to help us understand site usage, and to tailor our advertising on third party sites. Read about Cookies and view our Privacy Policy at the bottom of each page on our website at any time. I understand Your browser doesn t have JavaScript enabled. The site may not display or function as intended. Re-enable JavaScript to get the best experience. A JavaScript execution error has occurred somewhere on this page. The page may not function as intended. Try refreshing before continuing.

Using risk adjustment analytics to precision target interventions

By Pulse8 Payers stratify premiums for a given benefits package by the member s relationship to the policy holder, and if permitted, by age or gender. This stratification discourages enrolling higher-risk, hence unprofitable, members. Risk-adjustment (RA) aligns premiums with the cost of caring for members with documented conditions, removing that incentive and encouraging the enrollment of higher risk members.¹ The magnitude of these adjustments can be thousands of dollars per member each year and can easily exceed the typical profit margin of plans.¹ Therefore, complete, accurate and ongoing sizing of these opportunities drive the payer s strategy.² ³ Gaps are closed by confirming each member s open  conditions from claims or reviews of medical records, which can be expensive. However, confirmations supply needed revenues for their care, and sophisticated risk-adjustment analytics can identify undiagnosed conditions for earlier, more effective care.² ³ Let s examine

FRPS

FRPS
rps.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rps.org Daily Mail and Mail on Sunday newspapers.

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.